Japan Regenerative Medicine Laws Take Effect, Encourage Industry
This article was originally published in PharmAsia News
Executive Summary
Japan has formally enacted new legislation governing the development, approval and use of regenerative medicines, including induced pluripotent stem (iPS) cells, in a move welcomed by companies both inside and outside the country.